NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Genmab A/S (CO: GMAB)

 
GMAB Technical Analysis
5
As on 28th Mar 2025 GMAB STOCK Price closed @ 1364.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1984.53 & Strong Sell for SHORT-TERM with Stoploss of 2133.55 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

GMABSTOCK Price

Open 1390.00 Change Price %
High 1400.50 1 Day -35.00 -2.50
Low 1360.50 1 Week -13.50 -0.98
Close 1364.00 1 Month -140.00 -9.31
Volume 184824 1 Year -900.00 -39.75
52 Week High 2330.00 | 52 Week Low 1322.00
 
CO Denmark Most Active Stocks
SAS 0.01 0.00%
NOVO-B 474.05 -1.36%
VWS 100.10 -2.25%
CONFRZ 0.02 0.00%
ALMB 16.60 -1.19%
DANSKE 232.00 -2.32%
ASTRLS 1.15 8.49%
TRYG 165.30 0.18%
GN 114.10 2.15%
GREENH 0.36 5.88%
 
CO Denmark Top Gainers Stocks
HYDRCT 0.60 46.34%
HYPE 3.66 22.00%
DKIEEU 249.00 15.81%
SAME 1.45 10.69%
SAME 1.45 10.69%
WIRTEK 6.40 10.34%
ASTRLS 1.15 8.49%
GJ 68.00 6.25%
VIRO 8.00 5.96%
GREENH 0.36 5.88%
 
CO Denmark Top Losers Stocks
VALUER 0.25 -21.88%
BLVIS-A 0.40 -18.37%
LEDIBOND 0.29 -17.14%
STENO 0.34 -10.53%
HAPPY 0.18 -10.00%
SCAPE 0.11 -8.33%
STRINV 0.92 -8.00%
PARKST-A 11.10 -7.50%
MAPS 0.86 -6.52%
MAPS 0.86 -6.52%
 
 
GMAB
Daily Charts
GMAB
Intraday Charts
Whats New @
Bazaartrend
GMAB
Free Analysis
 
GMAB Important Levels Intraday
RESISTANCE1441.08
RESISTANCE1416.36
RESISTANCE1401.08
RESISTANCE1385.80
SUPPORT1342.20
SUPPORT1326.92
SUPPORT1311.64
SUPPORT1286.92
 
GMAB Forecast March 2025
4th UP Forecast1811.06
3rd UP Forecast1667.69
2nd UP Forecast1579.06
1st UP Forecast1490.44
1st DOWN Forecast1237.56
2nd DOWN Forecast1148.94
3rd DOWN Forecast1060.31
4th DOWN Forecast916.94
 
GMAB Weekly Forecast
4th UP Forecast2021.11
3rd UP Forecast1810.37
2nd UP Forecast1680.11
1st UP Forecast1549.85
1st DOWN Forecast1178.16
2nd DOWN Forecast1047.89
3rd DOWN Forecast917.63
4th DOWN Forecast706.89
 
GMAB Forecast2025
4th UP Forecast3283.29
3rd UP Forecast2667.76
2nd UP Forecast2287.29
1st UP Forecast1906.82
1st DOWN Forecast821.18
2nd DOWN Forecast440.71
3rd DOWN Forecast60.24
4th DOWN Forecast-555.29
 
 
GMAB Other Details
Segment EQ
Market Capital 191580389376.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
GMAB Address
GMAB
 
GMAB Latest News
 
Your Comments and Response on Genmab A/S
 
GMAB Business Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. Address: Kalvebod Brygge 43, Copenhagen, Denmark, 1560
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service